Publication Name	World Journal of Clinical Cases
Manuscript ID	80540
Country	China

Category	Oncology
Manuscript Type	Case Report
Article Title	Multidisciplinary treatment of a patient with severe immune checkpoint inhibitor-induced colitis: A case report
Manuscript Source	Unsolicited Manuscript
All Author List	Lu Lu, Li Sha, Yu Feng and Liang Yan
Funding Agency and Grant Number	Funding Agency Grant Number Shanghai Municipal Health Commission, Shanghai Muricipal Administrator of Traditional Chinese Medicine NO. ZY (2021-2023)-0201-02
Corresponding Author	Liang Yan, PhD, Associate Chief Physician, Department of General Surgery, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, No. 185 Pu'an Road, Huangpu District, Shanghai 200021, China. yanliang0831@163.com
Key Words	Immune checkpoint inhibitor; Colitis; Programmed cell death ligand 1; Infliximab; Laparoscopic surgery; Case report
Core Tip	Immune checkpoint inhibitors (ICIs) sometimes lead to diarrhea and colitis, which are routinely treated with immunosuppressive therapy. For ICI-related colitis with ineffective medical treatment, timely surgical intervention could prevent the death of patients.
Citation	Lu L, Sha L, Feng Y, Yan L. Multidisciplinary treatment of a patient with severe immune checkpoint inhibitor-induced colitis: A case report. World J Clin Cases 2022; 10(35): 13108-13114

Received	2022-10-02 06:26
Peer-Review Started	2022-10-02 06:27
To Make the First Decision
Return for Revision	2022-10-21 01:27
Revised	2022-11-02 06:38
Second Decision	2022-11-23 03:13
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2022-11-23 10:30
Articles in Press	2022-11-23 10:30
Publication Fee Transferred
Edit the Manuscript by Language Editor	2022-11-20 12:56
Typeset the Manuscript	2022-12-02 05:59

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com